Ronquest NA, Paret K, Gould I, Barnett CL, Mladsi (she/her) DM. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports. J Manag Care Spec Pharm. 2021 Nov;27(11):1601-12. doi: 10.18553/jmcp.2021.27.11.1601
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Prefer Adherence. 2016 Jun 8;2016(10):1025-35. doi: 10.2147/PPA.S102760
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States. Patient Prefer Adherence. 2016 Jan 21;10:45-55. doi: 10.2147/PPA.S93320.
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004 Jan 1;20(12):1883-93. doi: 10.1185/030079904X11510.